Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stent worries may help Plavix

Executive Summary

FDA's Circulatory System Devices Panel recommends extended use of Sanofi-Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) for reducing risk of thrombosis associated with drug-eluting stents. During its Dec. 7-8 meeting, the panel suggested FDA align DES labeling with American Heart Association guidelines that the antiplatelet therapy be taken for up to a year if a patient does not exhibit excessive bleeding. An observational study published in the Dec. 5 Journal of the American Medical Association found better outcomes were achieved the longer patients took Plavix, up to one year. FDA is considering changing DES labeling to reflect the need for anticlotting regimens that last longer than the three months recommended for Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent and the six months recommended for Boston Scientific's Taxus paclitaxel-eluting stent...

You may also be interested in...



Trials To Assess Dual Antiplatelet Therapy For Combatting DES Thrombosis

Chicago - Major drug-eluting stent manufacturers are negotiating to design a clinical trial to help determine the optimal time period for using dual antiplatelet therapy to avoid thrombosis in patients with a drug-eluting stent, according to Boston Scientific VP-Interventional Cardiology Marketing Eric Simso

Off-Label Drug Promotion On The Agenda For Rep. Waxman, States

Rep. Henry Waxman, D-Calif., is taking a closer look at the marketing practices of five pharmaceutical companies, a probe that follows several state lawsuits over off-label drug promotion

Cardiology Groups Stress Year-Long Antiplatelet Therapy For Stent Patients

"Strong" consideration should be given to avoiding drug-eluting stents in patients who are not expected to continue dual antiplatelet therapy for a full 12 months, according to a 1science advisory posted online by leading medical organizations

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel